The aim of this multicenter, double-blind, randomized, placebo-controlled phase II study was to evaluate the efficacy and clinical safety of a natural hypolipidemic compound, coenzyme A (CoA) capsule in Chinese patients with moderate hypertriglyceridemia.
Hyperlipidemia plays important roles in the development and progression of atherosclerosis. 1, 2 Modulating lipid levels that mostly focused on the control of cholesterol has been shown to reduce the development of atherosclerosis and incidence of cardiovascular disease (CVD). 3 Although hypercholesterolemia is an established risk factor for CVD, approximately 40% of the patients with CVD had total cholesterol (TC) levels below the normal range, and most of these patients had high levels of triglyceride (TG) and low levels of high-density lipoprotein cholesterol (HDL-C). 4 Although the association between TG level and risk of CVD remains controversial, 5, 6 long-term observational study showed elevated fasting TG level was associated with increased risk of the occurrence of CVD and cardiac death after complete coronary revascularization. [7] [8] [9] So, other lipoproteins such as TG and HDL-C could be the potential therapeutic targets to decrease residual cardiovascular risk. 10, 11 There are several types of lipid-lowering drugs available for patients with dyslipidemia. The 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (also known as statins) are the most effective agents available for the management of hyperlipidemia and prevention of major cardiovascular events. 12 
R E T R A C T E D
Although statin-based therapy is commonplace in primary and secondary prevention, economical, clinical, and safety issues are still existing. 13, 14 Fenofibrate, an activator of peroxisome proliferator-activated receptor-a, is another most commonly used agent indicated for the treatment of dyslipidemia, especially in patients with hypertriglyceridemia. 15 Safety issues are also considered, especially drug-induced hepatotoxicity when it is used with statins. 16 So, there is ongoing research into new, safer, and more effective agents to be used alone or in combination with the existing cardiovascular drugs. 17 Coenzyme A (CoA) is a ubiquitous essential cofactor that plays a central role in the metabolism of carboxylic acids, including short-chain and long-chain fatty acids, as well as carbohydrate and protein. In the metabolic pathway of lipid, CoA participates in fatty acid b-oxidation and promotes TG catabolism. 18, 19 Previous research revealed that insufficiency of CoA in vivo influenced fatty acid b-oxidation catabolism and impaired clearance of TG from plasma, 20, 21 which was supposed to be one plausible reason resulting in type IIb and type IV hyperlipoproteinemia. In addition, epidemiological studies showed that the prevalence of serum lipids level increased with age, 22 which may be related to the reduction in CoA synthesis in aging individuals. 19 Moreover, studies on animals have given evidence to prove that supplement of CoA had normalizing activity on plasma lipids in dyslipidemia. 23 Pantethine is a versatile and very well-tolerated hypolipidemic agent that can decrease serum TG, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B levels, while increasing HDL-C and apolipoprotein AI levels. [24] [25] [26] [27] [28] [29] [30] Pantethine is the disulfide of pantetheine, which per se occurs as a derivative of CoA. Theoretically, antihyperlipidemic effect of CoA should be more direct and effective than pantethine. Research using rabbit and rat models proved that oral high-dose CoA could relieve fasting hyperlipidemia and insulin resistance induced by a high-fat diet . 23, 31 So far there is no sufficient clinical research data to support the efficacy of oral CoA in patients with dyslipidemia. The present study evaluated, for the first time, the effectiveness and safety of oral CoA.
Methods

Participants and Study Design
Participant and Inclusion Criteria. Eligible patients were male and female, 18 to 75 years of age with moderate hypertriglyceridemia (TG level at 2.3-6.5 mmol/L), according to the China National Cholesterol Education Programme diagnostic criteria of hyperlipidemia. 32 Major exclusion criteria included TC >7.5 mmol/L or LDL-C >3.6 mmol/L; body mass index (BMI) >30 kg/m 2 ; secondary dyslipidemia of any cause; pregnancy; breastfeeding, and women of childbearing potential not using chemical or mechanical contraception or with a positive pregnancy test; history of alcohol or drug dependence; an acute coronary syndrome within 6 months of screening; active liver disease or hepatic dysfunction with elevations of alanine aminotransferase (SGPT) or aspartate aminotransferase (SGOT) >3 times the upper normal limit; renal impairment as defined by serum creatinine !179 mmol/L; unexplained serum creatine phosphokinase (CK) >3 times the upper normal limit; uncontrolled diabetes, hypothyroidism, or hypertension; concurrent therapy with other lipid-modifying drugs; or participants in serious or unstable medical or psychological condition that compromised the participants safety or participation in the trial. History of CVD and other comorbidities was determined through questionnaires administered at the time of study enrollment. Patients with New York Heart Association class IIIb or IV heart failure or with a left ventricular ejection fraction known to be <30% also were excluded. The study protocol conformed to the Declaration of Helsinki and was approved by the hospital's institutional ethics committee. Prior to any study procedures, written informed consent was obtained from each study participant by investigators of each center. The trial has been registered under Clinical-Trials.gov Identifier NCT01645046.
Study Design. The study was an 8-week prospective, multicenter, randomized, double-blind, placebo-controlled phase II study conducted between October 2008 and January 2010 at 6 centers in China. Any lipid-lowering drugs were discontinued at the time of screening. Patients with TG levels between 2.3 and 6.5 mmol/L entered a 4-week run-in period. Dietary counseling was given. Patients were asked to adhere to their usual isocaloric diet during the course of the trial and to avoid extensive physical exercise the days before each tracer study. On completing the run-in phase, patients who still met the inclusion criteria with changes in TG levels less than 20% were randomized to receive CoA 200 U/d, CoA 400 U/d, or placebo (Shanghai Baolong Pharmaceutical Group Co., Ltd. Qingpu District, Shanghai). Patients were allocated numbers as they entered the study, and a computer-generated randomization scheme was used to determine treatment allocation as each patient became eligible. Treatment codes for each patient were provided to each center in a sealed envelope, and investigators were unaware of the treatment codes until the envelope was opened at the randomization visit. Follow-up visits occurred at 4 and 8 weeks after initiation of therapy. At each visit, a routine physical examination including height, weight, heart rate, and blood pressure was performed and fasting (12 hours) blood samples were collected to determine serum lipoproteins, SGPT, SGOT, creatinine, CK, and fasting blood glucose levels on a Hitachi 7170A analyzer by a specialist who was unaware of this study. Central laboratory was used in the study. All blood samples were sent to the central laboratory in insulated packaging within 48 hours. The incidence and severity of adverse events (AEs), including abnormal laboratory values (liver enzymes, creatinine, and CK) were recorded to assess tolerability. Also, the relationship of AEs with the treatment was assessed. Medication compliance and the proper use of drugs were assessed. Education on healthy lifestyles was reinforced.
The primary end point was the percentage change in serum TG levels from the baseline to 4 and 8 weeks of treatment. The secondary end point was the percentage change from the
baseline to 4 and 8 weeks of treatment in serum TC, LDL-C, and HDL-C levels.
Statistical Analysis
According to the State Food and Drug Administration regulations for phase II clinical trials and about 20% dropout rate in a previous study (a previous multicenter study we conducted in 2005 to evaluate the lipid-lowering effect of CoA capsule 100 U/d and CoA 200 U/d in patients with hypertriglyceridemia; data not reported), it was calculated that 294 screening participants were required to achieve 90% power for a 2-sided significance level of 5%. Participants were evaluated based on an intention to treat (ITT) population, which consisted of participants who had a baseline reading, at least 1 efficacy reading, and at least 1 dose of medication. If a participant was withdrawn prior to week 8, the last value after baseline was taken as the week 8 assessment. The continuous variables were expressed as the group mean + 1 (standard deviation). The analyses were performed using the analysis of covariance model, with factors fitted for treatment and the predose (baseline) lipid parameter value as a covariate. The results were presented as least squares means (LSM) and the difference between the LSM with P values and associated 95% confidence intervals. In addition, the percentage change in lipid parameters has been summarized. Data were analyzed in SAS/STAT, version 9.13.
Results
Patient Characteristics
Of 294 patients screened, 244 (69.7% male and 30.3% female) were randomized into the treatment groups (79 for CoA 200 U daily, 84 for CoA 400 U daily, and 81 for placebo), received at least 1 dose of the study drug, and had baseline and week 8 lipid measurements available (ITT population). Fifty patients were discontinued before randomization; in 43 participants (Figure 1) . Baseline demographic and clinical characteristics, risk factors, and medications for 244 randomized patients are presented in Table 1 . Sex distribution, clinical characteristics of study participants, BMI, systolic and diastolic blood pressure, frequency of risk factors (type 2 diabetes mellitus and hyperuricemia), and medications were similar between the 2 treatment groups. In total, 13 (11.3%) patients had type 2 diabetes and 13 (11.3%) had hyperuricemia. In addition, there was no significant change in BMI from baseline to week 8 among the 3 groups.
Efficacy
After treatment for 4 weeks, the reduction in TG level among the placebo, CoA 200 U/d, and CoA 400 U/d groups was 5.2%, 9.1%, and 12.4%, respectively. After treatment for 8 weeks, the reduction in TG level among the placebo, CoA 200 U/d, and CoA 400 U/d groups was 1.7%, 14.3%, and 31.1%, respectively. The TG levels in CoA 200 U/d and CoA 400 U/d groups significantly decreased after treatment for 4 weeks and 8 weeks when compared to the baseline(P < .01). Compared to placebo, TG levels in CoA 200 U/d and CoA 400 U/d groups significantly decreased after treatment for 8 weeks (P < .01), and the difference between CoA 200 U/d and CoA 400 U/d groups was also significant (P < .01). There was no significant difference in TG levels among the 3 groups during treatment for 4 weeks (P ¼ .54; Table 2 ). There was a trend that TC was slightly lowered and HDL-C mildly increased in CoA 400 U/d group at week 8, but this difference did not reach statistical significance. No significant difference was found in LDL-C levels among the 3 groups (Table 3 ).
Safety
The occurrence of AEs was similar among the 3 groups. Both study doses of CoA treatments were generally well tolerated, and the incidence of AEs was low. No SAE occurred in the study. The proportion of patients who discontinued study treatment because of AEs did not differ statistically in the CoA 200 U/d group 0.0%, in the CoA 400 U/d group 2.4%, and in the placebo group 1.2% (Table 4 ). Mean changes from baseline in levels of SGPT, SGOT, creatinine, and CK at week 4 and week 8 were small and similar among the 3 groups, and generally unremarkable (data not shown).
Discussion
Hyperlipidemia is an important contributory factor to the development of atherosclerosis and as such is recognized as a major risk factor for CVD. Consequently, lipid-lowering therapy is very important for the prevention and treatment of CVD. 1, 2 Although statins are recommended as first-line drug treatment for patients with high risk of CVD, 12, 32 new and safer agents are being developed, especially those targeting the residual risk of hypertriglyceridemia or low HDL-C level. 9, 17, 33, 34 The CoA is one of the most important biologically active compounds that are essential for metabolism of the 3 major forms of energy (fat, carbohydrates, and protein). It is present in all living cells, which functions as an acyl group carrier and plays a central role in the tricarboxylic acid cycle. The CoA has a clearly defined role in promoting fat decomposition, regulating the synthesis of key enzyme of fatty acids synthetic metabolism as well as in facilitating fatty acid b-oxidation. As a cofactor for a number of oxidative and biosynthetic reactions in intermediary metabolism, CoA is also involved in the oxidation of fatty acids. 18, 19 The CoA may modulate serum concentration of TG via inhibiting the assembly and secretion of very low-density lipoprotein apolipoprotein B within the hepatocyte. 35 Therefore, it is presumed that CoA functions as regulator on the lipid metabolism, and has a lipid lowering effect in hyperlipidemia . 36 But the mechanism of the TG-lowering effect of CoA has not been clearly established. In this study, we demonstrated that serum TG was significantly decreased in patients with hypertriglyceridemia after 8 weeks of treatment with CoA 400 U daily. Although no significant difference was found, there was a trend that TC was slightly lowered and HDL-C mildly increased in CoA 400 U/d group at week 8. Our study confirms the TG-lowering effect of CoA, as reported previously.
Previous studies showed that intravenous administration of CoA could accelerate TG catabolism and thereby lower TG 
levels by inducing fatty acid oxidation response. It was suggested that CoA injection could effectively lower postprandial serum TG level increase in patients with fasting hypertriglyceridemia. 20, 21 Although sufficient evidences supported the lipid-lowering effect of CoA, it was inconvenient for patients to receive chronic intravenous CoA administration. So, oral CoA capsule was developed. Animal studies showed that fasting TC and LDL-C levels were significantly reduced with oral CoA administration at 800 and 1500 U/kg per day for 20 days, and TG level was also decreased at a higher dose, suggesting its potential therapeutic role in dyslipidemia. 23 Available lipid-lowering agents have proved their efficacy in both clinical trials and experimental settings, but their long-term toxicity is giving rise to worry concerning their clinical use. 37, 38 Dyslipidemia may need almost lifelong therapy; thus, many people prefer natural products instead of chemical drugs. The percentage is 18.9% in the United States and may be much higher in some other countries. 39 In our study, it was shown that the adverse reactions of CoA administration were mild, and the frequency of their occurrence was very low, similar to placebo. There was no occurrence of myopathy or obvious damage in liver and kidney function. Furthermore, the incidence of gastrointestinal tract symptoms and complications induced by CoA therapy were also rare. All these evidences demonstrate that CoA is a well-tolerated lipid-lowering agent.
Study Limitations
This is the first study to evaluate the efficacy and clinical safety of CoA capsule in participants with moderate dyslipidemia. As a phase II study, the trial was conducted on a relative small sample, and the follow-up duration was relatively short. Although we did not aim to evaluate the long-term effect of CoA in this study, it is necessary to know whether an antihyperlipidemic Xuan et al 5
agent is suitable for long-term therapy. Some future studies with larger patient numbers and longer follow-up duration will be required to establish long-term safety and efficacy of oral CoA treatment. Second, for the safety sake of the patients enrolled in this placebo-controlled trial, the TC, LDL-C, and HDL-C levels were almost normal. So the lipid-lowering effects of CoA on patients with mixed dyslipidemia still remain unknown. Further studies are needed to evaluate the efficacy of CoA for mixed dyslipidemia as well as the combined effect of CoA and other lipid-lowering drugs. Third, the patients enrolled in this trial are all Chinese participants, so the results of this trial may not be directly extrapolated to other races without any international multicenter clinical trial result.
Conclusions
Taken together, in patients with moderate dyslipidemia, serum TG levels were effectively reduced with oral CoA capsule. Both CoA doses were well tolerated.
